1. Home
  2. ENVB vs ARTL Comparison

ENVB vs ARTL Comparison

Compare ENVB & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENVB
  • ARTL
  • Stock Information
  • Founded
  • ENVB 1994
  • ARTL 2011
  • Country
  • ENVB United States
  • ARTL United States
  • Employees
  • ENVB N/A
  • ARTL N/A
  • Industry
  • ENVB Biotechnology: Pharmaceutical Preparations
  • ARTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENVB Health Care
  • ARTL Health Care
  • Exchange
  • ENVB Nasdaq
  • ARTL Nasdaq
  • Market Cap
  • ENVB 3.1M
  • ARTL 3.1M
  • IPO Year
  • ENVB N/A
  • ARTL N/A
  • Fundamental
  • Price
  • ENVB $1.32
  • ARTL $23.88
  • Analyst Decision
  • ENVB Strong Buy
  • ARTL Strong Buy
  • Analyst Count
  • ENVB 1
  • ARTL 2
  • Target Price
  • ENVB $10.00
  • ARTL $25.00
  • AVG Volume (30 Days)
  • ENVB 107.1K
  • ARTL 1.9M
  • Earning Date
  • ENVB 08-11-2025
  • ARTL 08-12-2025
  • Dividend Yield
  • ENVB N/A
  • ARTL N/A
  • EPS Growth
  • ENVB N/A
  • ARTL N/A
  • EPS
  • ENVB N/A
  • ARTL N/A
  • Revenue
  • ENVB N/A
  • ARTL N/A
  • Revenue This Year
  • ENVB N/A
  • ARTL N/A
  • Revenue Next Year
  • ENVB N/A
  • ARTL N/A
  • P/E Ratio
  • ENVB N/A
  • ARTL N/A
  • Revenue Growth
  • ENVB N/A
  • ARTL N/A
  • 52 Week Low
  • ENVB $1.01
  • ARTL $4.92
  • 52 Week High
  • ENVB $11.55
  • ARTL $28.60
  • Technical
  • Relative Strength Index (RSI)
  • ENVB 57.52
  • ARTL 72.07
  • Support Level
  • ENVB $1.19
  • ARTL $9.11
  • Resistance Level
  • ENVB $1.28
  • ARTL $28.60
  • Average True Range (ATR)
  • ENVB 0.06
  • ARTL 4.19
  • MACD
  • ENVB 0.02
  • ARTL 1.92
  • Stochastic Oscillator
  • ENVB 91.48
  • ARTL 79.31

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: